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Conclusions: The treatment planification of HDR 
brachytherapy with CT images and 3D dosimetry allows to 
know the dose received in the volume of the organs at risk 
and also a good optimisation of the treatment. 
The treatment was very well tolerated and there was no 
grade 3-4 toxicity in our patients.  
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Purpose/Objective: Toxicity evaluation of exclusive adjuvant 
vaginal cuff High Dose Rate Brachytherapy (HDR-BT) in 
patients with endometrial cancer. 
Materials and Methods: From 2009 to date, 53 patients were 
treated in our institution with HDR-BT, with a median age of 
65 years. 52 patients underwent hysterectomy for 
endometrioid cancer and 1 for transitional cell carcinoma. 
FIGO and grading staging were 14-IA, 35-IB, 4-IIA, 8-G1, 31-
G2, 14-G3. No patients received external-beam radiation 
therapy or chemotherapy. Before Computed Tomography (CT) 
simulation, women underwent a gynecological examination in 
order to determine the size of the vaginal cylinder that will 
fit the patient. CT simulation was performed with 2.5 mm CT 
slice thickness with empty rectum and the treatment cylinder 
in the vaginal cavity. Before CT scan patients drank 500 cc of 
water after voiding bladder ; this preparation was repeated 
before each fraction in order to reproduce bladder's filling 
conditions used for the planning. Upper 3-3.5 cm of the 
vaginal vault were treated. Patients received five fractions 
each of 600 cGy for a total dose of 3000 cGy prescribed at 
0.5 cm from the applicator surface. During the radiation 
therapy course, patients received supportive therapy with 
hyaluronic acid vaginal suppositories. A low-fat diet with the 
addition of lactobacilli was suggested. Use of vaginal dilators 
was not prescribed. Gastrointestinal (GI) and Genitourinary 
(GU) toxicity were evaluated by RTOG score. Late toxicity 
effects were also analysed in 26 patients with a median 
follow-up of 37 months by using the RTOG late-effect score. 
According to our protocol, gynaecological exams were 
scheduled every 3 months for two years and then every 6 
months up to five years. 
Results: Eighteen patients experienced acute GU toxicity: 10 
Grade 1 (G-1), 6 G-2, and 2 G-3. Regarding early GI toxicity, 
9 cases of G-1 toxicity and 2 of G-2 occurred.Four patients 
experienced GU late toxicity: 3 G-2 and 1 G-3. No one 
complained of GI late toxicity. Ten patients presented 
vaginal stenosis during the gynaecological examinations. This 
side effect made the patients' follow-up difficult because of 
greater difficulty in viewing the vaginal vault; also four 
women complained of dyspareunia 
Conclusions: In our experience, vaginal-vault HDR-BT 
treatment is well tolerated, with a very low GI toxicity score. 
Vaginal stenosis appears to be the principal disorder observed 
in long-term follow-up. In order to improve this safe 
technique, we think that could be reasonable to prescribe 
the use of the vaginal dilator not in all patients, but only in 
those women in which the stenosis occur. 
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Purpose/Objective: The aim of this study was to assess 
through radiobiological evaluation the ability of the hybrid 
inverse planning optimization (HIPO) system to produce dose 
distributions comparable or superior to the clinically 
accepted ones devised using graphical optimization (GRO) for 
cervical cancer patients treated with pulsed-dose-rate 
brachytherapy. 
Materials and Methods: Six cervical cancer patients treated 
with external radiotherapy and pulsed-dose-rate 
brachytherapy were included in this study. The patients 
received 50 Gy (25 x 2 Gy) as external radiotherapy and 24 
Gy (3 x 8 Gy) as pulsed-dose-rate brachytherapy planned 
using GRO performed in Oncentra® Brachy treatment 
planning (Nucletron, an Elekta Company). An alternative 
brachytherapy plan was made in HIPO using volumetric 
